Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Sep;190(5):e279-e282.
doi: 10.1111/bjh.16935. Epub 2020 Aug 10.

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience

Vallari Shah  1 , Thinzar Ko Ko  1 , Mark Zuckerman  2 , Jennifer Vidler  3 , Sobia Sharif  1 , Varun Mehra  1 , Shreyans Gandhi  1 , Andrea Kuhnl  1 , Deborah Yallop  1 , Daniele Avenoso  1 , Carmel Rice  1 , Robin Sanderson  1 , Anita Sarma  1 , Judith Marsh  1   4 , Hugues de Lavallade  1 , Pramila Krishnamurthy  1 , Piers Patten  1   4 , Reuben Benjamin  1   4 , Victoria Potter  1 , M Mansour Ceesay  1   3 , Ghulam J Mufti  1   4 , Sam Norton  5 , Antonio Pagliuca  1   4 , James Galloway  5 , Austin G Kulasekararaj  1   4
Affiliations
Comparative Study

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience

Vallari Shah et al. Br J Haematol. 2020 Sep.
No abstract available

Keywords: COVID-19; SARS-CoV-2; haematological malignancies; lymphoid malignancies; myeloid malignancies; stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Fig 1
Fig 1
Competing risk regression model evaluating mortality rate at day 28. Crude mortality rate (A), age/gender adjusted mortality rate (B), mortality rate by diagnostic category (C, lymphoid vs. myeloid), mortality rate by treatment intensity (D, intensive vs. non‐intensive vs. ‘watch and wait’) in patients with underlying haematological malignancies compared with general cohort without haematological malignancies.
See this image and copyright information in PMC

References

    1. Guan, WJ , Ni, ZY , Hu, Y , Liang, WH , Ou, CQ & He, JX , et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. - PMC - PubMed
    1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS‐CoV‐2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. - PMC - PubMed
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, et al. Clinical Outcome of Coronavirus Disease 2019 in haemato‐oncology patients. Br J Haematol. 2020. Online ahead of print. 10.1111/bjh.16852 - DOI - PMC - PubMed
    1. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID‐19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–45. - PMC - PubMed

MeSH terms